neamine has been researched along with angiogenin in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (33.33) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hirukawa, S; Hu, GF; Olson, KA; Tsuji, T | 1 |
| Hirukawa, S; Hu, GF; Hu, MG; Ibaragi, S; Li, S; Sadow, PM; Yoshioka, N | 1 |
| Bottero, V; Chandran, B; Dutta, S; Johnson, KE; Sadagopan, S; Veettil, MV | 1 |
| Hu, GF; Ibaragi, S; Kishimoto, K; Sasaki, A; Yoshida, S; Yoshioka, N | 1 |
| An, S; Hu, G; Liu, Y; Wu, Y; Zhang, X | 1 |
| Hu, GF; Liu, YP; Wu, YL; Wu, YX; Zhang, XY | 1 |
6 other study(ies) available for neamine and angiogenin
| Article | Year |
|---|---|
Neamine inhibits xenografic human tumor growth and angiogenesis in athymic mice.
Topics: Active Transport, Cell Nucleus; Aminoglycosides; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Nucleus; Cell Proliferation; Endothelial Cells; Framycetin; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Ribonuclease, Pancreatic; Umbilical Veins; Xenograft Model Antitumor Assays | 2005 |
Neamine inhibits prostate cancer growth by suppressing angiogenin-mediated rRNA transcription.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Framycetin; Humans; Male; Mice; Prostatic Neoplasms; Proto-Oncogene Proteins c-akt; Ribonuclease, Pancreatic; RNA, Ribosomal; Transcription, Genetic; Xenograft Model Antitumor Assays | 2009 |
Kaposi's sarcoma-associated herpesvirus-positive primary effusion lymphoma tumor formation in NOD/SCID mice is inhibited by neomycin and neamine blocking angiogenin's nuclear translocation.
Topics: Animals; Antineoplastic Agents; Ascites; Body Weight; Cell Line, Tumor; Disease Models, Animal; Framycetin; Herpesvirus 8, Human; Lymphoma, Primary Effusion; Mice; Mice, SCID; Neomycin; Ribonuclease, Pancreatic; Spleen; Survival Analysis; Treatment Outcome | 2013 |
Neamine inhibits oral cancer progression by suppressing angiogenin-mediated angiogenesis and cancer cell proliferation.
Topics: Angiogenesis Inducing Agents; Animals; Cell Line, Tumor; Cell Proliferation; Disease Progression; Framycetin; Humans; Immunohistochemistry; In Situ Nick-End Labeling; Mice; Mice, Nude; Mouth Neoplasms; Neovascularization, Pathologic; Protein Transport; Ribonuclease, Pancreatic; Xenograft Model Antitumor Assays | 2014 |
Pharmacokinetics of neamine in rats and anti-cervical cancer activity in vitro and in vivo.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Area Under Curve; Biological Availability; Cell Proliferation; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Female; Framycetin; Half-Life; HeLa Cells; Human Umbilical Vein Endothelial Cells; Humans; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Rats; Rats, Sprague-Dawley; Ribonuclease, Pancreatic; Tissue Array Analysis; Up-Regulation; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2015 |
Neamine inhibits growth of pancreatic cancer cells in vitro and in vivo.
Topics: Adult; Animals; Antibiotics, Antineoplastic; Carcinoma; Cell Line, Tumor; Cell Proliferation; Framycetin; Humans; Ki-67 Antigen; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Middle Aged; Pancreatic Neoplasms; Platelet Endothelial Cell Adhesion Molecule-1; Ribonuclease, Pancreatic | 2016 |